Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

DISEASE CHARACTERISTICS:

Histologically confirmed diagnosis of one of the following:

Low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL)

The following histologies are eligible:

Small lymphocytic lymphoma
Lymphoplasmacytoid lymphoma
Follicular center grades 1, 2, or 3 lymphoma
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type
Nodal marginal zone B-cell lymphoma
Relapsed or refractory after 2 prior treatment regimens or 1 anthracycline regimen
Diffuse large B-cell NHL or mantle cell lymphoma in first or second relapse
Transformed NHL, defined as low-grade NHL transformed to diffuse large B-cell lymphoma, with no more than 1 relapse since transformation

Age 18 and over Recovered from prior immunotherapy Life expectancy At least 3 months Recovered from prior chemotherapy

More than 4 weeks since prior major surgery and recovered
More than 4 weeks since prior anticancer therapy recovered from prior radiotherapy

Exclusion criteria:

No major bleeding within the past 4 weeks No uncontrolled hypertension No stroke within the past 4 weeks

No active infection
No other active nonmalignant disease
No known G6PD deficiency
No history of porphyria
No other condition that would preclude study participation
No human anti-mouse antibodies
No known history of HIV
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No prior radioimmunoconjugate therapy
No prior exposure to murine antibodies other than rituximab
More than 4 weeks since prior rituximab
No history of failed stem cell collection